HOUSE_OVERSIGHT_024905.jpg
2.1 MB
Extraction Summary
1
People
3
Organizations
0
Locations
1
Events
1
Relationships
3
Quotes
Document Information
Type:
Financial research report / equity research
File Size:
2.1 MB
Summary
This document is page 89 of a Cowen Collaborative Insights research report dated February 25, 2019. It provides a detailed analysis of Phase 3 clinical trials for the drug Epidiolex (produced by GW Pharma) for the treatment of Lennox-Gastaut syndrome (LGS), including trial designs, efficacy statistics regarding seizure reduction, and adverse event data. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was collected as part of a congressional investigation.
People (1)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient |
Listed in the sidebar watermark: 'This report is intended for michael.cella@cowen.com'
|
Organizations (3)
| Name | Type | Context |
|---|---|---|
| Cowen |
Investment bank/financial services firm producing the report (Cowen Collaborative Insights)
|
|
| GW Pharma |
Pharmaceutical company being analyzed; source of the data charts
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024905'
|
Relationships (1)
Email address michael.cella@cowen.com listed in watermark
Key Quotes (3)
"This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited."Source
HOUSE_OVERSIGHT_024905.jpg
Quote #1
"Epidiolex reduced all seizures by 41% vs. a 14% reduction for placebo (p=0.0005)"Source
HOUSE_OVERSIGHT_024905.jpg
Quote #2
"There was one death in the Epidiolex group from acute respiratory distress syndrome, but it was not considered treatment related."Source
HOUSE_OVERSIGHT_024905.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document